Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

Rhea-AI Summary

Castle Biosciences (NASDAQ: CSTL) will present a company overview at the Leerink Partners Healthcare Crossroads Conference on May 29, 2024, at 2:00 p.m. Eastern time. The executive management will provide insights into the company's innovative tests that guide patient care. A live audio webcast of the presentation will be available on the Castle Biosciences website, with a replay accessible post-broadcast.

Positive

• Castle Biosciences is set to present at a prestigious healthcare conference, potentially increasing investor interest.
• The company's focus on innovative tests to guide patient care highlights its commitment to advancing healthcare solutions.

Negative

• The press release lacks specific financial or clinical data updates, which may leave investors seeking more substantive information.
• No new product launches or major business developments were mentioned, potentially limiting the impact on stock performance.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515189022/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

When will Castle Biosciences present at the Leerink Partners Healthcare Crossroads Conference?

Castle Biosciences will present on May 29, 2024, at 2:00 p.m. Eastern time.

How can I access the live webcast of Castle Biosciences' presentation?

The live webcast will be available at Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/.

Will a replay of the Castle Biosciences presentation be available?

Yes, a replay will be available on the Castle Biosciences website after the live broadcast concludes.

What is the stock symbol for Castle Biosciences?

Castle Biosciences' stock symbol is CSTL.

What is the focus of Castle Biosciences' business?

Castle Biosciences focuses on improving health through innovative tests that guide patient care.